A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn's Disease

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 6, 2006, Pages 754-759

  Braat, Henri ^a   Rottiers, Pieter ^b   Hommes, Daniel W ^a   Huyghebaert, Nathalie ^c   Remaut, Erik ^b   Remon, Jean Paul ^c   van Deventer, Sander J H ^a   Neirynck, Sabine ^b,d   Peppelenbosch, Maikel P ^e   Steidler, Lothar ^b,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EUDRAGIT; INFLIXIMAB; INTERLEUKIN 10; PLACEBO; PROTON PUMP INHIBITOR; THYMIDYLATE SYNTHASE;

ABDOMINAL PAIN; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DNA MODIFICATION; DRUG COATING; DRUG SAFETY; ENTERIC COATED TABLET; FECES ANALYSIS; FLATULENCE; GENE SEQUENCE; GENE THERAPY; HEADACHE; HUMAN; LACTOCOCCUS LACTIS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; SMALL INTESTINE OBSTRUCTION; STOMACH PAIN; TRANSGENE; TREATMENT WITHDRAWAL; VOMITING;

C-REACTIVE PROTEIN; CROHN DISEASE; GENE THERAPY; HUMANS; INTERLEUKIN-10; LACTOCOCCUS LACTIS; ORGANISMS, GENETICALLY MODIFIED; TABLETS, ENTERIC-COATED; THYMIDYLATE SYNTHASE; TRANSGENES;

EID: 33744933432     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.03.028     Document Type: Article

References (20)

1. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
2. Egan L.J., and Sandborn W.J. Advances in the treatment of Crohn's disease. Gastroenterology 126 (2004) 1574-1581
3. Kuhn R., Lohler J., Rennick D., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
4. Fedorak R.N., Gangl A., Elson C.O., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. the Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119 (2000) 1473-1482
5. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
6. Tilg H., van Montfrans C., van den Ende A., et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50 (2002) 191-195
7. Steidler L., Hans W., Schotte L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289 (2000) 1352-1355
8. Gruzza M., Fons M., Ouriet M.F., et al. Study of gene transfer in vitro and in the digestive tract of gnotobiotic mice from Lactococcus lactis strains to various strains belonging to human intestinal flora. Microb Releases 2 (1994) 183-189
9. Klijn N.WeerkampA.H.d.VosW.M. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl Environ Microbiol 61 (1995) 2771-2774
10. Steidler L., Neirynck S., Huyghebaert N., et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21 (2003) 785-789
11. Hommes D.W., and van Deventer S.J. Endoscopy in inflammatory bowel diseases. Gastroenterology 126 (2004) 1561-1573
12. Huyghebaert N., Vermeire A., Neirynck S., et al. Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. Eur J Pharm Biopharm 60 (2005) 349-359
13. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
14. Vandenbroucke K., Hans W., Van Huysse J., et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127 (2004) 502-513
15. Watanabe T., Kitani A., Murray P.J., et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5 (2004) 800-808
16. Gasson M.J. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 154 (1983) 1-9
17. Bringel F., Van Alstine G.L., and Scott J.R. A host factor absent from Lactococcus lactis subspecies lactis MG1363 is required for conjugative transposition. Mol Microbiol 5 (1991) 2983-2993
18. Syvanen M. Churning out safer microbes for drug delivery. Nat Biotechnol 21 (2003) 758-759
19. Bradbury J. Beyond pills and jabs. researchers develop new ways to get drugs to the right place at the right time. Lancet 362 (2003) 1984-1985
20. Baker M. Better living through microbes. Nat Biotechnol 23 (2005) 645-647